Which patients with resectable pancreatic cancer truly benefit from oncological resection: is it destiny or biology?

Abstract

Pancreatic cancer has a dismal prognosis. A technically perfect surgical operation may still not provide a survival advantage for patients with technically resectable pancreatic cancer. Appropriate selection of patients for surgical resections is an imminent issue. Recent studies have provided an important clue on what serum biomarkers may be used to select out the patients who would unlikely benefit from the surgical resection.

Keywords:

• pancreatic cancer
• surgery
• serum biomarker

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.